Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/26159
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNguyen-Dumont, Tú-
dc.contributor.authorDowty, James G-
dc.contributor.authorMacInnis, Robert J-
dc.contributor.authorSteen, Jason A-
dc.contributor.authorRiaz, Moeen-
dc.contributor.authorDugué, Pierre-Antoine-
dc.contributor.authorRenault, Anne-Laure-
dc.contributor.authorHammet, Fleur-
dc.contributor.authorMahmoodi, Maryam-
dc.contributor.authorTheys, Derrick-
dc.contributor.authorTsimiklis, Helen-
dc.contributor.authorSeveri, Gianluca-
dc.contributor.authorBolton, Damien M-
dc.contributor.authorLacaze, Paul-
dc.contributor.authorSebra, Robert-
dc.contributor.authorSchadt, Eric-
dc.contributor.authorMcNeil, John-
dc.contributor.authorGiles, Graham G-
dc.contributor.authorMilne, Roger L-
dc.contributor.authorSouthey, Melissa C-
dc.date2021-03-24-
dc.date.accessioned2021-04-08T02:43:39Z-
dc.date.available2021-04-08T02:43:39Z-
dc.date.issued2021-03-24-
dc.identifier.citationCancers 2021; 13(7): 1495en
dc.identifier.issn2072-6694
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/26159-
dc.description.abstractWhile gene panel sequencing is becoming widely used for cancer risk prediction, its clinical utility with respect to predicting aggressive prostate cancer (PrCa) is limited by our current understanding of the genetic risk factors associated with predisposition to this potentially lethal disease phenotype. This study included 837 men diagnosed with aggressive PrCa and 7261 controls (unaffected men and men who did not meet criteria for aggressive PrCa). Rare germline pathogenic variants (including likely pathogenic variants) were identified by targeted sequencing of 26 known or putative cancer predisposition genes. We found that 85 (10%) men with aggressive PrCa and 265 (4%) controls carried a pathogenic variant (p < 0.0001). Aggressive PrCa odds ratios (ORs) were estimated using unconditional logistic regression. Increased risk of aggressive PrCa (OR (95% confidence interval)) was identified for pathogenic variants in BRCA2 (5.8 (2.7-12.4)), BRCA1 (5.5 (1.8-16.6)), and ATM (3.8 (1.6-9.1)). Our study provides further evidence that rare germline pathogenic variants in these genes are associated with increased risk of this aggressive, clinically relevant subset of PrCa. These rare genetic variants could be incorporated into risk prediction models to improve their precision to identify men at highest risk of aggressive prostate cancer and be used to identify men with newly diagnosed prostate cancer who require urgent treatment.en
dc.language.isoeng
dc.subjectaggressive Prostate canceren
dc.subjectgene panel testingen
dc.subjectgenetic risk factorsen
dc.subjectpredispositionen
dc.titleRare Germline Pathogenic Variants Identified by Multigene Panel Testing and the Risk of Aggressive Prostate Cancer.en
dc.typeJournal Articleen
dc.identifier.journaltitleCancersen
dc.identifier.affiliationDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USAen
dc.identifier.affiliationCESP Inserm U1018, Faculté de Médecine-Univ. Paris-Sud, Faculté de Médecine-UVSQ, Université Paris-Saclay, 94805 Villejuif, Franceen
dc.identifier.affiliationGustave Roussy, 94805 Villejuif, Franceen
dc.identifier.affiliationSurgery (University of Melbourne)en
dc.identifier.affiliationCESP Inserm U1018, Faculté de Médecine-Univ. Paris-Sud, Faculté de Médecine-UVSQ, Université Paris-Saclay, 94805 Villejuif, Franceen
dc.identifier.affiliationPrecision Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC 3168, Australiaen
dc.identifier.affiliationDepartment of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Melbourne, VIC 3010, Australiaen
dc.identifier.affiliationCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC 3010, Australiaen
dc.identifier.affiliationCancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC 3004, Australiaen
dc.identifier.affiliationDepartment of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australiaen
dc.identifier.doi10.3390/cancers13071495en
dc.type.contentTexten
dc.identifier.orcid0000-0002-6217-0182en
dc.identifier.orcid0000-0002-1049-5129en
dc.identifier.pubmedid33804961
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Sep 22, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.